 | Up a level |
Journal Article
Joerger, Markus, Cassier, Philippe, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Gruellich, Carsten, Grande, Enrique, Navarro, Alejandra, Park, Se Hoon, Gillessen, Silke, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter and Schuler, Martin H. (2018). Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. J. Clin. Oncol., 36 (6). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Joerger, Markus, Cassier, Philippe Alexandre, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Grullich, Carsten, Grande, Enrique, Navarro, Alejandro, Park, Se Hoon, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter and Schuler, Martin H. (2018). Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Kempf, Emmanuelle, Penel, Nicolas, Tournigand, Christophe, Gajate, Pablo, Tan, Daniel Shao-Weng, Cassier, Philippe, Nogova, Lucia, Cathomas, Richard, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Sayehli, Cyrus, Navarro, Alejandro, Park, Se Hoon, Piciu, Ana-Maria, Bender, Sebastian, Nogai, Hendrik, Ellinghaus, Peter, Joerger, Markus and Schuler, Martin H. (2020). Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression. J. Clin. Oncol., 38 (6). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
von Tresckow, Bastian, Gundermann, Stefan, Eichenauer, Dennis A., Aulitzky, Walter Erich, Goebeler, Mariele, Sayehli, Cyrus, Bacchus, Liza, Hauns, Bernhard, Mais, Anna, Hentsch, Bernd, Kohihof, Hella, Krauss, Rolf, Krauss, Babett, Baumgartner, Roland, Vitt, Daniel and Engert, Andreas (2014). First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study). J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
von Tresckow, Bastian, Sayehli, Cyrus, Aulitzky, Walter E., Goebeler, Maria-Elisabeth, Schwab, Matthias, Braz, Eunice, Krauss, Babett, Krauss, Rolf, Hermann, Frank, Bartz, Rene and Engert, Andreas (2019). Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. Eur. J. Haematol., 102 (2). S. 163 - 174. HOBOKEN: WILEY. ISSN 1600-0609